Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Altimmune

Amgen

Eli Lilly

Novo Nordisk

Pfizer

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.

Factbox: Weight-loss drugs: the next gold rush

A top competitor announced plans to move forward with a late-stage weight loss candidate today. Viking's weight-loss candidate is several years behind from a development standpoint.

Why Viking Therapeutics Stock Is Crashing Today

Axsome Therapeutics

Cue Biopharma

With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks to buy. In 2023 alone, pharmaceutical and biotech companies spent about $85 billion on acquisitions.

3 Biotech Stocks to Buy as Companies Ink Major Deals

Bristol-Myers

Bionano Genomics

GlaxoSmithKline

Inmode Ltd

Inspire Medical Systems Inc

Revance Therapeutics

Investing in healthcare stocks can be a wise decision for those looking to become wealthy in the long term. Some of the best healthcare stocks to buy are firms that are developing highly effective drugs for prevalent diseases for which there are no real effective treatments.

7 Healthcare Stocks to Make You the Millionaire Next Door

Viking Therapeutics is riding the obesity-drug fanfare initiated by Novo Nordisk. But its candidates won't be on the market for at least a few years.

After Blasting Off 881% in 1 Year, Is Viking Therapeutics Still a Good Buy?

Alibaba

Intellia Therapeutics

Alibaba has tremendous growth opportunities in AI. Intellia Therapeutics' gene-editing therapies hold the potential to be big winners.

Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money.

DermTech Inc

Nano-X Imaging

Nano-X is marketing a different type of X-ray system. DermTech's Smart Sticker system could change dermatology.

If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position

Viking Therapeutics has a few drugs that have the potential to generate billions in revenue. The problem is that they are in early-stage trials, so there's ample uncertainty with the business.

Could Viking Therapeutics Stock Help You Become a Millionaire?

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals and Viking Therapeutics have been on fire over the past year. Even so, both companies still look incredibly undervalued relative to their long-term growth potential.

Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics?

Structure Therapeutics Inc

Novo Nordisk's medicines for obesity and diabetes are spawning many copycats. Viking Therapeutics' stock is soaring thanks to its favorable early results.

Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years

Viking Therapeutics is a biotech with multiple potential blockbuster drugs in its portfolio. Encouraging trial results have made investors bullish about the stock's prospects.

This Red-Hot Growth Stock Has Soared 885% in Just 12 Months

Roth Capital Partners initiated coverage on Viking Therapeutics with a $32 per-share price target. The private investment banking firm also appears confident in the prospects of the company's lead assets.

Why Viking Therapeutics Stock Is Heating Up Today

Two stocks in the healthcare sector have already doubled this year, and they could climb much higher, according to Wall Street. Viking Therapeutics is a clinical-stage biotech with an experimental treatment that could treat millions of underserved liver disease patients.

2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street

Now is a great time to start accumulating top biotech stocks. The biotech boom is red-hot.

3 Biotech Stocks Sitting on Huge-Upside Catalysts

Ginkgo Bioworks Holdings

Moderna

These biotech stocks are swinging for the fences. They may hit homers, they may strike out.

Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich

Darling Ingredients

Tenet Healthcare

Chemed

Lantheus Holdings

Merus

Carrols Restaurant Group

Stock screeners can help investors identify stocks to buy based on a variety of criteria. In fact, one helpful predictor of stock price growth can be found with analyst ratings.

7 Stocks That Wall Street Analysts Are Loving in May

Cabaletta Bio

Community Health Systems

Exact Sciences

Novavax

Organogenesis Holdings

Ultragenyx Pharmaceutical

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

TipRanks reveals the top 10 health care sector analysts of the past decade

The FTC's attempt to block the merger between Amgen and Horizon Therapeutics is weighing on small- and mid-cap biotech stocks. Shares of Viking Therapeutics are sinking in lockstep with its broader peer group today.

Why Viking Therapeutics Stock Is Buckling Today

A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.

Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study

The Viking Therapeutics, Inc. primary endpoint of phase 2b VOYAGE study, using VK2809 for the treatment of patients with non-alcoholic steatohepatitis, was achieved with statistical significance. Phase 2b VOYAGE 52-week biopsy data is expected to be released in the 1st half of 2024.

Viking Therapeutics: Latest NASH Data Reinforces Drive Towards Finish Line

Viking's long-awaited midstage NASH trial results were announced today, and they didn't disappoint. Investors bid up the biotech's shares in response to this positive clinical update, despite a dour day for pharma stocks in general.

Why Viking Therapeutics Stock Bolted Higher Today

Viking unveiled promising test results Tuesday for a liver disease drug, but VKTX stock reversed its premarket gain and sank at the open. The post Top 1% Biotech Viking Therapeutics Backs Off Its Record Run On NASH Enthusiasm appeared first on Investor's Business Daily.

Top 1% Biotech Viking Therapeutics Backs Off Its Record Run On NASH Enthusiasm

Viking Therapeutics Inc (NASDAQ:VKTX) today announced a win for its experimental drug to treat patients with a type of fatty liver disease called non-alcoholic steatohepatitis (NASH).

Bulls Blast Viking Therapeutics Stock on Trial Data

Viking Therapeutics unveiled promising test results Tuesday for a liver disease treatment, sending top-rated VKTX stock to a record high. The post Why Top 1% Biotech Viking Therapeutics Is At The Brink Of A Record High appeared first on Investor's Business Daily.

Why Top 1% Biotech Viking Therapeutics Is At The Brink Of A Record High

Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in Liver Fat from Baseline to Week 12 in Patients Receiving VK2809 as Compared to Placebo Up to 52% Mean Liver Fat Reduction Observed in VK2809-Treated Patients Up to 85% of Patients Experienced at Least a 30% Relative Reduction in Liver Fat Statistically Significant Reductions in LDL-C, Triglycerides, and Atherogenic Lipoproteins Observed Adverse Events, Including GI-Related AEs, Similar Among VK2809-Treated Patients vs. Placebo Conference Call Scheduled for 8:00 a.m.

Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

News for Viking Therapeutics Stock (VKTX)